(FM) Inmunología
Departamento académico
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (16)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Regional and intratumoral adoptive T-cell therapy
Immuno-Oncology and Technology, Vol. 24
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2022
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
2021
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
2020
-
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469
2019
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
2018
-
Introducing a new series: Immunotherapy facts and hopes
Clinical Cancer Research
-
Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1
2017
-
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936
2016
-
Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
2013
-
Agonist antibodies to TNFR molecules that costimulate T and NK cells
Clinical Cancer Research, Vol. 19, Núm. 5, pp. 1044-1053
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine